Patients with DM had a significantly shorter median progression-free survival (PFS) and overall survival . The time on pembrolizumab treatment was shorter in diabetic patients, with only 19.6% remaining on treatment at 12 months compared to 31.7% of the nondiabetic patients . More work is needed to verify our findings and explore similar effects in other cancer entities .